Showing 1 - 16 results of 16 for search 'Johannes Ettl', query time: 0.31s Refine Results
  1. 1
    Results of recurrent in-service exhaust gas measurements with an EU stage IV forest harvester fuelled with rapeseed oil within the emission durability period
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Transient emission and fuel consumption measurements on plant oil tractors
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Evaluation of pure rapeseed oil as a renewable fuel for agricultural machinery based on emission characteristics and long-term operation behaviour of a fleet of 18 tractors
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    MRI based neuroanatomical segmentation in breast cancer patients: leptomeningeal carcinomatosis vs. oligometastatic brain disease vs. multimetastastic brain disease
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search